Literature DB >> 10098217

Possible role of neuropeptides in obsessive compulsive disorder.

C J McDougle1, L C Barr, W K Goodman, L H Price.   

Abstract

The most consistent finding in clinical research of obsessive compulsive disorder (OCD) is the significant treatment advantage of potent serotonin uptake inhibitors (SUIs) over other classes of antidepressant and antianxiety drugs. Clinical neurobiological studies of OCD, however, have yielded limited and inconsistent evidence for significant fundamental abnormalities in monoamine systems including serotonin, norepinephrine and dopamine. Furthermore, one-third to one-half of OCD patients do not experience a clinically meaningful improvement with SUI treatment. Investigation beyond the monoamine systems may be necessary in order to more fully understand the pathophysiology of obsessive-compulsive symptoms and develop improved treatments. Evidence from preclinical studies suggests that neuropeptides may have important influences on memory acquisition, maintenance and retrieval; grooming, maternal, sexual and aggressive behavior; fixed action patterns; and stereotyped behavior; these phenomena may relate to some features of OCD. In addition, extensive interactions have been identified in the brain between neuropeptidergic and monoaminergic systems, including co-localization among specific populations of neurons. The purpose of this review is to present the current knowledge of the role of neuropeptides in the clinical neurobiology of children, adolescents and adults with OCD focusing primarily on results from pharmacological challenge and cerebrospinal fluid studies. Where evidence exists, developmentally regulated differences in neuropeptide function between children and adolescents versus adults with OCD will be emphasized; these data are intended to underscore the potential importance of establishing the age of symptom onset (childhood versus adult) in individual patients with OCD participating in clinical neurobiological investigations. Likewise, where information is available, differences in measures of neuropeptides between patients with non-tic-related OCD versus tic-related OCD will be highlighted; these data will demonstrate the critical value of diagnostic precision, as these two particular subtypes of OCD may have different neurochemical underpinnings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098217     DOI: 10.1016/s0306-4530(98)00046-8

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  11 in total

Review 1.  Autism and oxytocin: new developments in translational approaches to therapeutics.

Authors:  Joshua J Green; Eric Hollander
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 2.  Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.

Authors:  Leonardo F Fontenelle; Sanne Oostermeijer; Ben J Harrison; Christos Pantelis; Murat Yücel
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 3.  Maternal programming: Application of a developmental psychopathology perspective.

Authors:  Laura M Glynn; Mariann A Howland; Molly Fox
Journal:  Dev Psychopathol       Date:  2018-08

4.  A CASE OF PERIPARTUM OBSESSIVE-COMPULSIVE DISORDER: The Potential Role of Corticosteroids, Gonadal Steroids, and the Neuropeptide Oxytocin in its Pathogenesis.

Authors:  David R Spiegel; Kathyrn Sommese; Anastasia Turenkov; Niels Naimon
Journal:  Innov Clin Neurosci       Date:  2019-05-01

Review 5.  The cognitive-affective neuroscience of obsessive-compulsive disorder.

Authors:  D J Stein; W K Goodman; S L Rauch
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

6.  Safety of treatment of obsessive compulsive disorder in pregnancy and puerperium.

Authors:  Shirin Namouz-Haddad; Irena Nulman
Journal:  Can Fam Physician       Date:  2014-02       Impact factor: 3.275

7.  Adenylate-cyclase activity in platelets of patients with obsessive-compulsive disorder.

Authors:  D Marazziti; S Baroni; L Palego; I Masala; G Consoli; M Catena Dell'osso; G Giannaccini; A Lucacchini
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

Review 8.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

9.  Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.

Authors:  Mats B Humble; Kerstin Uvnäs-Moberg; Ingemar Engström; Susanne Bejerot
Journal:  BMC Psychiatry       Date:  2013-12-23       Impact factor: 3.630

Review 10.  From Autism to Eating Disorders and More: The Role of Oxytocin in Neuropsychiatric Disorders.

Authors:  Adele Romano; Bianca Tempesta; Maria Vittoria Micioni Di Bonaventura; Silvana Gaetani
Journal:  Front Neurosci       Date:  2016-01-12       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.